As World Vaccine Congress Washington 2025 comes to a close, we reflect on an impactful three days of collaboration, innovation and scientific exchange. It was an honour for P95, a leading vaccine research CRO, to take part in one of the most influential global gatherings dedicated to vaccines and public health.
A Strong Presence at Booth 329
Throughout the three-day congress, Booth 329 became a hub for conversations on vaccines, clinical trials and epidemiology. Visitors had the opportunity to meet our global team and learn how P95 works as a vaccine research CRO across all trial phases. We connected with long-standing collaborators and welcomed new partners, all driven by a shared passion for advancing vaccine research.
Shining a Spotlight on Epidemiology in Clinical Development
Our CEO Thomas Verstraeten, delivered a standout presentation titled “Clinical Development Driven by Epidemiological Research”. During this session, Thomas shared our perspective on how epidemiology supports smarter, faster, and more targeted clinical development, particularly for vaccines in complex global environments. Drawing from P95’s real-world experience as a vaccine research CRO, he highlighted our work in vaccine effectiveness studies, post-marketing surveillance, and disease burden modeling across five continents.
Our Commitment to Global Health Solutions
From our founding in Belgium to our expanding footprint in the United States, Africa, Asia, and Latin America, P95, a globally recognized vaccine research CRO, continues to deliver tailored, high-quality clinical and epidemiology solutions in even the most complex environments. Our work spans over 500 clinical trials in 30+ countries, with a specialized focus on infectious diseases and vaccine development.
Looking Ahead
World Vaccine Congress Washington was a powerful reminder of the global community dedicated to improving health through vaccines. Let’s continue the conversation! We invite you to reach out through our contact form or meet us at an upcoming event.
0 Comments